Increasing incidence of recent hepatitis D virus infection in HIV-infected patients in an area hyperendemic for hepatitis B virus infection

Clinical Infectious Diseases

Volumn 58, Issue 11, 2014, Pages 1625-1633

  Hung, Chien Ching ^a,b,c   Wu, Shih Min ^d   Lin, Pi Han ^d   Sheng, Wang Huei ^a   Yang, Zong Yu ^d   Sun, Hsin Yun ^a   Tsai, Mao Song ^e   Lee, Kuan Yeh ^a   Huang, Ming Siang ^d   Chang, Shu Fang ^d   Su, Yi Ching ^a   Liu, Wen Chun ^a   Chang, Sui Yuan ^a,d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b China Medical University Hospital   (China)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Case control study; Seroconversion; Seroincidence; Sexually transmitted diseases; Syphilis

Indexed keywords

AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; BILIRUBIN; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; INTEGRASE INHIBITOR; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; REAGINIC ANTIBODY; RNA DIRECTED DNA POLYMERASE INHIBITOR; HEPATITIS ANTIBODY; VIRUS DNA; VIRUS RNA;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DISEASE EXACERBATION; ENDEMIC DISEASE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; SEROCONVERSION; SUPERINFECTION; SYPHILIS; VIREMIA; VIRUS LOAD; BLOOD; CASE CONTROL STUDY; CLASSIFICATION; COHORT ANALYSIS; COMPLICATION; DNA SEQUENCE; GENETICS; HEPATITIS D; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; MOLECULAR GENETICS; PLASMA; RETROSPECTIVE STUDY; RISK FACTOR; VIROLOGY;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; DNA, VIRAL; FEMALE; HEPATITIS ANTIBODIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS D; HEPATITIS DELTA VIRUS; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; PLASMA; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

EID: 84900419809     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu127     Document Type: Article

References (31)

1. Rizzetto M, Hoyer B, Canese MG, Shih JW, Purcell RH, Gerin JL. delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A 1980; 77:6124-8.
2. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011; 378:73-85.
3. Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin Liver Dis 2012; 32:211-9.
4. Calle Serrano B, Manns MP, Wedemeyer H. Hepatitis delta and HIV infection. Semin Liver Dis 2012; 32:120-9.
5. Rizzetto M. Hepatitis D: thirty years after. J Hepatol 2009; 50:1043-50.
6. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7:31-40.
7. Heidrich B, Manns MP, Wedemeyer H. Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep 2013; 15:31-8.
8. Ji J, Sundquist K, Sundquist J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst 2012; 104:790-2.
9. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-6.
10. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009; 136:1609-17.
11. Sun HY, Chang SY, Yang ZY, et al. Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. J Clin Microbiol 2012; 50:781-7.
12. Sun HY, Ko WC, Tsai JJ, et al. Seroprevalence of chronic hepatitis B virus infection among Taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination. Am J Gastroenterol 2009; 104:877-84.
13. Chang SY, Yang CL, Ko WS, et al. Molecular epidemiology of hepatitis D virus infection among injecting drug users with and without human immunodeficiency virus infection in Taiwan. J Clin Microbiol 2011; 49:1083-9.
14. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007; 106:148-55.
15. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012; 57:730-5.
16. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142:333-41.
17. William Tong CY, Asher R, Toby M, et al. A re-assessment of the epidemiology and patient characteristics of hepatitis D virus infection in inner city London. J Infect 2013; 66:521-7.
18. Gish RG, Yi DH, Kane S, et al. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol 2013; 28:1521-5.
19. Soriano V, Grint D, d?Arminio Monforte A, et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS 2011; 25:1987-92.
20. Liaw YF, Chiu KW, Chu CM, Sheen IS, Huang MJ. Heterosexual transmission of hepatitis delta virus in the general population of an area endemic for hepatitis B virus infection: a prospective study. J Infect Dis 1990; 162:1170-2.
21. Wu JC, Lee SD, Govindarajan S, et al. Sexual transmission of hepatitis D virus infection in Taiwan. Hepatology 1990; 11:1057-61.
22. Mele A, Franco E, Caprilli F, et al. Hepatitis B and delta virus infection among heterosexuals, homosexuals and bisexual men. Eur J Epidemiol 1988; 4:488-91.
23. Rosenblum L, Darrow W, Witte J, et al. Sexual practices in the transmission of hepatitis B virus and prevalence of hepatitis delta virus infection in female prostitutes in the United States. JAMA 1992; 267:2477-81.
24. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381:468-75.
25. Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58: 1537-47.
26. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364:322-31.
27. Kabacam G, Onder FO, Yakut M, et al. Entecavir treatment of chronic hepatitis D. Clin Infect Dis 2012; 55:645-50.
28. Chevaliez S, Hezode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013; 58:676-83.
29. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-63.
30. Gatanaga H, Hayashida T, Tanuma J, Oka S. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection. Clin Infect Dis 2013; 56:1812-9.
31. Sheng WH, Chuang YC, Sun HY, et al. Prophylactic effect of lamivudine-based antiretroviral therapy on incident hepatitis B virus infection among HIV-infected patients. Clin Infect Dis 2013; 57: 1504-6.